Cardiovascular mortality has remained high in patients on peritoneal dialysis (PD) due to the high prevalence of various cardiovascular complications including coronary artery disease, left ventricular hypertrophy and dysfunction, heart failure, arrhythmia (especially atrial fibrillation), cerebrovascular disease, and peripheral arterial disease. In addition, nearly a quarter of PD patients develop sudden cardiac death as the terminal life event. Thus, it is essential to identify effective treatment that may lower cardiovascular mortality and improve survival of PD patients. The
over 90% (2, 3) . Left ventricular hypertrophy predicts an increased risk of mortality and adverse cardiovascular outcomes in PD patients (3) . In particular, it is associated with an increased risk of heart failure/circulatory congestion (4) . In PD patients, the reported prevalence of heart failure is estimated around 35% and even higher, up to 60% among those whose condition was previously complicated by heart failure (4) . Notably, more than half of the PD patients with heart failure have normal ejection fraction, indicating that diastolic dysfunction is an important contributing factor to heart failure in these patients (5) . The presence of heart failure is a powerful predictor of adverse clinical outcomes in dialysis patients (4) . Data from the United States Renal Data System suggest that heart failure is a very frequent cause of hospitalization in dialysis patients, and the mortality rate after heart failure was 83% at 3 years (6) . Furthermore, nearly 25% of all deaths in dialysis patients, including those receiving PD, are sudden cardiac death in nature (7, 8) , of which the underlying mechanisms remain far from clear. Impaired left ventricular systolic dysfunction is one of the key predictors of sudden cardiac death in PD patients (8) . On the other hand, a recent analysis from a large nationwide retrospective cohort from Taiwan showed that PD patients are at increased risk of stroke in comparison with an age-and sex-matched reference cohort, though the risk of hemorrhagic stroke appeared lower compared with hemodialysis patients (9) . Peripheral arterial disease is also exceedingly common in PD patients, with a reported prevalence of 28.5% (range, 4.8% -47%) in PD patients, the majority of whom have subclinical peripheral arterial disease (10) . The prevalence of peripheral arterial disease is increasing with the increasing global incidence of diabetes as the cause of end-stage renal disease. Peripheral arterial disease is also a strong predictor of adverse clinical outcomes and mortality (10) . Last but not least, atrial fibrillation is an important, and also the most common, abnormal cardiac rhythm in dialysis patients. The exact prevalence in PD has not been determined but, in hemodialysis, it is estimated around 12.5 -27% and is associated with an increased risk of stroke (11, 12) .
The current publication forms the second International Society for Peritoneal Dialysis (ISPD) cardiovascular and metabolic guideline document, makes recommendations on assessment and management of coronary artery disease, left ventricular hypertrophy and dysfunction, heart failure, arrhythmia (specifically atrial fibrillation), cerebrovascular disease, peripheral vascular disease and sudden cardiac death. There are altogether 26 guideline statements of which only 5 statements are graded as level 1 or 'strong' recommendations, 18 statements are graded as level 2 or 'weak' recommendations and 3 statements are ungraded. Each guideline statement is provided with a brief rationale paragraph and key references. Full detailed rationale and evidence review tables are provided in the online publication. In addition, the workgroup has defined areas where evidence is clearly deficient and provided a list of suggestions for future research in each specific area. (13) . Whilst there are subtle differences between TnI and TnT in renal failure, these are unlikely to be clinically relevant. It is difficult to define a reference range in the normal population, and even more difficult in dialysis patients; thus, a single elevated troponin level without clinical correlates is unlikely to be helpful, apart from indicating an enhanced cardiovascular risk (14) . A rise in serial markers, along with appropriate clinical context, is the currently accepted definition of an acute coronary syndrome (15) . The difficulty lies in the definition of how much change constitutes a significant change. A 20% serial change is taken as ~3 standard deviation of change and assumes an analytical coefficient of variation of up to 7% (16).
3.1.2
We suggest asymptomatic peritoneal dialysis patients incidentally found to have high cardiac troponins without dynamic changes be considered as having an elevated cardiovascular risk (2B) and may benefit from investigation for underlying cardiac disease such as cardiac hypertrophy, dysfunction, or occult coronary artery disease (ungraded).
RATIONALE: There are limited data on the utility of a single troponin result. There are some data on the utility of troponin in transplant workup, but no good evidence that elevated troponin can be reduced by any intervention, or that intervention improves outcomes. Nevertheless, there may be a rationale for looking at patients with high troponin levels to see whether all cardiovascular risks have been appropriately addressed with interventions that potentially improve outcomes (for example, volume and blood pressure control to improve left ventricular hypertrophy or coronary artery angioplasty/bypass in those with proven coronary artery disease) but the evidence for this in PD is lacking (17).
3.1.3
We recommend a thorough history and physical examination in all patients initiating peritoneal dialysis therapy to identify any significant cardiac conditions including coronary artery disease, recent myocardial infarction, decompensated heart failure, significant arrhythmias, and severe valvular disease for further specific management. (1D) RATIONALE: Cardiovascular disease is under-diagnosed and under-treated in patients with chronic kidney disease (CKD), including those on PD (18, 19) . Identifying treatable disease is desirable. Many cardiovascular disease symptoms and signs may be masked in patients on dialysis (18, 19) . A good history and physical examination will identify many abnormalities or provide a clue to further workup. Moreover, it is not associated with any adverse effect or additional cost. RATIONALE: There is no evidence to suggest that universal screening for coronary artery disease is beneficial. Furthermore, it increases costs and may be harmful (20) .
Myocardial perfusion studies such as dobutamine stress echocardiography and thallium scintigraphy are useful in identifying patients with significantly increased risk of future myocardial infarction and coronary artery disease in both diabetic and non-diabetic end-stage renal disease patients (21, 22 RATIONALE: Data regarding the use of angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) for cardiovascular protection have remained scanty and there are virtually no hard outcome studies in PD patients. One randomized controlled trial (27) reported a non-significant 7% reduction in cardiovascular events after 24 months of treatment with an ACEI in hemodialysis patients compared with placebo in the intention to treat analysis. A secondary per-protocol analysis suggested a trend towards benefit in the composite cardiovascular endpoint with ACEIs. Another small open-labeled randomized trial suggested a reduction in mortality and cardiovascular events with an ARB compared with placebo but patients with background symptomatic cardiac disease were excluded (28). Cice et al. reported significant long-term survival and cardiovascular benefits and reduction in hospitalization for heart failure over 3 years by combining an ACEI with an ARB in hemodialysis patients with class II-III heart failure and systolic dysfunction (29) . Another recent meta-analysis suggested that left ventricular mass index may regress more with ARB treatment than without in CKD (30) . Given the overall very limited evidence, a weak recommendation was drawn in relation to the use of ACEIs or ARBs for cardiovascular disease in PD patients. (36) . However, a recent Cochrane review evaluating the effects of antiplatelet therapy on cardiovascular events, mortality, and bleeding in 11,701 patients with CKD and with either stable or no cardiovascular disease found that antiplatelet therapy was associated with uncertain effects on stroke and an increased risk of minor bleeding (37) . Given the unclear benefit of antiplatelet therapy for primary stroke prevention and the increased risk of bleeding in patients with CKD, we felt that PD patients should not routinely be prescribed antiplatelet therapy for primary prevention of cerebrovascular disease.
3.3.3
We suggest individualization of warfarin prescription for prevention of stroke in peritoneal dialysis patients with atrial fibrillation in view of an increased risk of bleeding and uncertain effects on cerebrovascular outcomes. (2D) RATIONALE: Although antithrombotic therapy is recommended by the AHA Guidelines for Primary Prevention of Stroke for patients with atrial fibrillation to prevent stroke (38) , all the trials upon which this recommendation was based excluded dialysis patients. A systematic review of 8 studies (including case series, cohort studies, and randomized controlled trials) evaluating warfarin therapy in hemodialysis patients found that the rates of major bleeding episodes for those receiving warfarin were approximately twice the rate expected in hemodialysis patients receiving either no warfarin or subcutaneous heparin (39) . Moreover, a systematic review and meta-analysis of 25 studies (including cross sectional and cohort studies) evaluating outcomes of stroke in dialysis patients with atrial fibrillation found that, while atrial fibrillation was associated with almost a 2-fold increased risk of stroke and mortality in these patients compared with dialysis patients without atrial fibrillation, overall, warfarin use did not appear to decrease the risk of the combined outcome of hemorrhagic and ischemic stroke, especially in the larger studies (40) . Thus, the risk-to-benefit ratio of warfarin for stroke prevention in dialysis patients, including patients on PD, with atrial fibrillation is uncertain and we feel should be individualized.
3.3.4
We do not recommend the use of novel oral anticoagulants to prevent stroke in atrial fibrillation in peritoneal dialysis patients. (1D) RATIONALE: While new oral anticoagulants are now available to prevent stroke in patients with atrial fibrillation, all these new oral anticoagulants are mostly cleared by the kidney and are contraindicated in patients with CKD stage 5 on dialysis (41, 42) . Thus, we do not recommend use of these new oral anticoagulants for stroke prevention in patients on PD with atrial fibrillation.
fatal myocardial infarctions, fatal strokes, and hospitalizations for worsening heart failure with carvedilol than with placebo. However, there are so far no randomized trials examining the efficacy of beta-blockers for cardiovascular protection in PD patients.
3.2.5
We suggest peritoneal dialysis patients already receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker be considered for treatment with a mineralocorticoid receptor antagonist. (2B) RATIONALE: Spironolactone has been shown to significantly reduce the progression of left ventricular mass index over a 24-month period and improve the rate of change of ejection fraction at 24 weeks in PD patients compared with controls (33) . A recent open-label, randomized controlled trial showed that adding spironolactone to ACEI or ARB significantly lowered the risk of reaching the primary composite endpoint of death from cardiovascular and cerebrovascular events and hospitalizations due to cardiovascular and cerebrovascular events and risk of all-cause deaths in oligoanuric hemodialysis patients (34 RATIONALE: Current available evidence is insufficient to draw any recommendation in relation to the use of thrombolytic agents as a treatment of acute ischemic stroke in patients on dialysis (43) . Thus, a very careful assessment of risks vs benefits must be undertaken before administering intravenous thrombolytics for treatment of acute ischemic stroke in dialysis patients, including patients on PD. RATIONALE: Although there are no studies comparing routine clinical evaluation of stage 5 CKD patients for peripheral arterial disease (PAD) vs evaluation only in response to symptoms, the Kidney Disease: Improving Global Outcomes (KDIGO) CKD Guidelines recommend that "adults with CKD be regularly examined for signs of PAD and be considered for usual approaches to therapy (1B)" (44) . Given the high prevalence of clinical and subclinical PAD in PD patients, especially among diabetics, and the adverse clinical outcomes associated with PAD, the workgroup felt that a strong recommendation should be given for regular clinical evaluation of PAD in PD patients.
3.4.2
We suggest an ankle-brachial index <0.9 be used to aid the diagnosis of peripheral arterial disease in peritoneal dialysis patients. (2D) RATIONALE: The most common screening test employed to detect PAD in studies of PD patients was the ankle-brachial index (ABI) using a cut-point of ≤0.9 to define PAD. This threshold has been reported to have a sensitivity of 95% and a specificity of 100% for PAD detection in patients without CKD, although there are no studies examining the sensitivity and specificity of ABI in PD (or hemodialysis or CKD) patients specifically. Using ABI has been recommended for general population screening in at-risk patients by the American College of Cardiology (ACC)/AHA (45, 46) or in patients with suspected PAD by the Trans-Atlantic Inter-Society Consensus Document on Management of Peripheral Arterial Disease (TASC II) guidelines (47).
3.4.3
We suggest a toe-brachial index ≤0.6 be used in addition to the ankle-brachial index to aid in the diagnosis of peripheral arterial disease in symptomatic patients in whom the ankle-brachial index is unreliable due to non-compressible vessels (such as when the anklebrachial index is ≥1.3). (2D) RATIONALE: In patients with abnormally high ABI values due to non-compressible vessels (for example those with medial arterial calcification), the AHA/ACC and TASC II guidelines recommend measuring the toe-brachial index (TBI) using a cut-point ≤0.6 to define PAD as toe arteries are less likely to be affected by vascular calcification than ankle arteries (45) (46) (47) . There are only 2 studies of TBI in PD patients, which did not evaluate the sensitivity and specificity of cut-point values and/or the clinical performance of ABI and TBI relative to color Doppler, angiography, or prediction of future limb vascular complications.
3.4.4
We suggest peritoneal dialysis patients with non-critical peripheral arterial disease receive supervised exercise therapy. (2C) RATIONALE: Exercise therapy has been found in general PAD patient populations with intermittent claudication to have equivalent effectiveness to percutaneous luminal angioplasty in a meta-analysis of 8 randomized controlled trials (48) and to produce significantly improved walking time, pain-free walking distance, and maximum walking distance (but not mortality, amputation, peak exercise calf blood flow or ABI) compared with usual care or placebo in a meta-analysis of 22 trials involving 1,200 participants (49) . There are no randomized controlled trials testing the efficacy of exercise therapy in CKD patients with PAD. However, given the overall benefits of exercise in CKD patients, the workgroup felt that a weak recommendation for prescribing supervised exercise therapy in PD patients with non-critical PAD was justified.
3.4.5
We suggest peritoneal dialysis patients with peripheral arterial disease be considered for antiplatelet therapy. (2D) RATIONALE: In a recent systematic review and meta-analysis (25,37) of 31 randomized controlled trials of 11,701 adult patients with CKD and stable or no cardiovascular disease, antiplatelet therapy was associated with a reduction in myocardial infarction and an increased risk of minor bleeding and uncertain effects on stroke, all-cause mortality, cardiovascular mortality, and major bleeding. None of these studies examined PD patients or the use of anti-platelet therapy as a treatment for PAD. The Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines (50) recommend CKD patients with PAD be treated with antiplatelet agents, as in the general population. However, the KDIGO Cardiovascular update (51) emphasizes that evidence is lacking and that bleeding risks may be increased. Given the current lack of randomized controlled trials and a high degree of uncertainty regarding the risk vs benefit associated with antiplatelet therapy in PD patients with PAD, the workgroup felt a weak recommendation was justified. RATIONALE: The exact prevalence of atrial fibrillation has not been determined in PD, but in hemodialysis it is estimated around 12.5 -27% and is much higher than the prevalence rates described for the general population. An even higher prevalence is described when Holter monitoring technique is employed (52, 53) . The risk of hospitalization due to atrial fibrillation increases linearly with the decrease in glomerular filtration rate (GFR). The mortality rates for dialysis patients with atrial fibrillation were also significantly higher than for control subjects (54) . Therefore, regardless of whether atrial fibrillation is an independent risk factor for mortality or represents a risk predictor, we recommend that atrial fibrillation be regularly screened in all PD patients, because it indicates a markedly increased risk for comorbidities and death. GUIDELINE 3.6 . SUDDEN CARDIAC DEATH 3.6.1 We suggest peritoneal dialysis patients with low ejection fraction, high troponin and N-terminal pro-brain natriuretic peptide levels and those who survive a previous tachyarrhythmic cardiac arrest be considered at high risk for sudden cardiac death. (2C) RATIONALE: Sudden cardiac death (SCD) is common in PD patients, accounting for around 25% of all deaths (55) . Heart failure is associated with an increased risk of SCD, and left ventricular systolic dysfunction emerged as the most significant predictor of SCD in a study based on PD patients (5) . Cardiac troponin T was associated with SCD independent of echocardiographic parameters but N-terminal pro-brain natriuretic peptide was associated with SCD only in the univariate analysis (8) . A retrospective analysis of hemodialysis patients showed that patients who survived an episode of tachyarrhythmic cardiac arrest presented an increased risk of SCD in the future (56).
3.6.2 We suggest beta blockers be considered for primary prevention of sudden cardiac death in high-risk peritoneal dialysis patients. (2D) RATIONALE: There are currently no randomized controlled trials that examined the effectiveness of various anti-arrhythmic agents in preventing SCD in PD patients, although some studies from CKD and hemodialysis patients suggest beta blockers may be associated with a reduced rate of SCD (57) . However, none of the studies examined SCD as the primary endpoint.
3.6. 3 We suggest an implantable cardioverter-defibrillator be considered for secondary prevention of sudden cardiac death in peritoneal dialysis patients who survive an episode of cardiac arrest confirmed as being the result of malignant ventricular arrhythmia (except those occurring within first 48 hours post-acute myocardial infarction). (2D) RATIONALE: Implantable cardioverter-defibrillator devices (ICDs) are the only interventions that appears to robustly reduce SCD in the setting of primary or secondary prevention in the general population (excluding those that occurred immediately post-myocardial infarction) (58) . There are so far no randomized controlled trials examining the use of ICDs for primary prevention of SCD in dialysis patients. However, there are observational data from hemodialysis patients showing that the use of ICDs may be associated with an improved survival in survivors of cardiac arrests (59) . Putting together the very limited evidence available, the workgroup suggests a weak recommendation statement be drawn regarding the use of ICD in PD patients who survive an episode of cardiac arrest confirmed to be resulting from malignant ventricular arrhythmia. • A randomized controlled trial to evaluate the efficacy of ACEI or ARB or its combination vs placebo in improving hard outcomes (namely mortality and cardiovascular events) in PD patients with or without baseline heart failure or other cardiac co-morbidity. • A randomized controlled trial to evaluate the efficacy of mineralocorticoid receptor antagonist vs placebo in improving hard outcomes (namely mortality and cardiovascular events) in PD patients with or without baseline heart failure or other cardiac co-morbidity. • A randomized controlled trial to evaluate and compare the various blood pressure targets in relation to hard outcomes in PD patients with and without baseline heart failure. • A randomized controlled trial to evaluate the efficacy of icodextrin in improving hard outcomes in PD patients with and without baseline heart failure. • A randomized controlled trial to evaluate the efficacy of oral activated vitamin D in improving hard outcomes in PD patients with and without baseline heart failure. • A randomized controlled trial to evaluate the efficacy of salt restriction in improving hard outcomes in PD patients with and without baseline heart failure. • A randomized controlled trial to evaluate the efficacy of cardiac resynchronization therapy in improving hard outcomes in PD patients with heart failure.
RESEARCH RECOMMENDATIONS

SECTION 3: Stroke
• A randomized controlled trial of antiplatelet therapy for the primary prevention of cerebrovascular disease in PD patients. • A randomized controlled trial of warfarin therapy for prevention of stroke in PD patients with atrial fibrillation.
SECTION 4: Peripheral Arterial Disease
• The diagnostic performance of ABI, TBI and other noninvasive tests for PAD should be formally evaluated in dialysis populations, including PD patients. • The impact of screening for PAD vs no screening on clinical outcomes in dialysis populations (including PD patients) should be evaluated by a randomized controlled trial. • A randomized controlled trial of supervised exercise therapy vs usual care to prevent PAD in PD patients. • A randomized controlled trial of statins vs matching placebo for primary prevention of PAD in PD patients. • A randomized controlled trial of supervised exercise therapy vs usual care for the treatment of PAD in PD patients. • A randomized controlled trial of cilostazol vs matching placebo for the treatment of PAD in PD patients. • A randomized controlled trial of naftidrofuryl oxalate vs matching placebo for the treatment of PAD in PD patients. • A randomized controlled trial of revascularization vs supportive medical care in PD patients with PAD and critical limb ischemia (primary endpoint -amputation; secondary endpoints including duration of hospitalization, mortality, costs, sepsis). • A randomized controlled trial of primary revascularization vs primary amputation in PD patients with PAD and critical limb ischemia.
SECTION 5: Arrhythmia
• Prospective analysis of the impact of various cardiac arrhythmia on clinical outcomes of PD patients. • Defining specific risk factors for various cardiac arrhythmias in the PD population.
SECTION 6: Sudden Cardiac Death
• Cohort studies and randomized controlled trials in the PD population should document SCD as a specific and standardized endpoint. • A randomized controlled trial of beta blockers for primary prevention of SCD in PD patients is warranted. • A randomized controlled trial of ICDs in the high-risk group of PD patients is warranted.
SECTION 7: Arterial Stiffness
• A randomized controlled trial of cardiovascular risk modification based on arterial stiffness measurements compared with conventional clinical evaluation in PD patients.
